Trial Profile
An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders; Epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 22 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.